Results 171 to 180 of about 28,869 (265)

Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China. [PDF]

Lancet Reg Health West Pac
Wu X, Ma P, Ruan L, Chen Y, Wang R, Song Y, Cai Y, Chen F, Zhang L, Fitzpatrick T, Li B, Wu G, Meng X, Fan S, Qiao Y, Gao Y, Hong Z, Zhang T, Zou M, Wang L, Fu Y, Su B, Zou J, Wang H, Zou H.   +24 more
europepmc   +1 more source

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort. [PDF]

HIV Med
Pierone G, Brunet L, Fusco JS, Sension MG, Dunbar MS, Gruber J, Dieterich DT, Fusco GP.   +7 more
europepmc   +1 more source

Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure-Editorial on "Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B". [PDF]

Korean J Gastroenterol
Lee SK.
europepmc   +1 more source

Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies. [PDF]

Infect Dis Ther
Antinori A, Yokomaku Y, Elinav H, Pullukçu H, de Wet J, Antela A, Lu PL, Sabranski M, Kim YS, Bonnet F, den Hollander J, Jackson A, Choy CY, Cai W, Zhang F, Thorpe D, Marongiu A, Harrison R, Jarrett J, Boffito M.   +19 more
europepmc   +1 more source

Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIV. [PDF]

J Antimicrob Chemother
Mainella VA, Branchford B, Nemkov T, Hosford S, Coyle RP, Johnson B, Choi YJ, Williams M, Zheng JH, Bushman L, Kiser JJ, Anderson PL, Brooks KM.   +12 more
europepmc   +1 more source

Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy. [PDF]

BMC Infect Dis
Li Q, Li J, Gao C, Zhao Y, Zhu L, Xiao J, Zhang F.   +6 more
europepmc   +1 more source

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +1 more source

Safety and Effectiveness of Biktarvy^® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. [PDF]

Infect Chemother
Kim SW, Peters J, Lang MG, Lee JA, Cha J, Kim YS.   +5 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR. [PDF]

Infect Chemother
Kim YS, Choi JY, Park DW, Kim SW, Kim TH, Ryu J, Harrison R, Lee JA, Park F, Lee SH.   +9 more
europepmc   +1 more source

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). [PDF]

Clin Infect Dis
Serrano-Villar S, Martín-Pedraza L, Tiraboschi J, Novella M, Cabello-Úbeda A, López-Cortés L, Busca C, Torralba M, Crusells MJ, Hidalgo-Tenorio C, Estrada V, Del Amo-de Palacios A, Díaz de Santiago A, Fons-Contreras M, Santos J, Bernal E, Montero-Alonso M, Troya J, Blanco JR, Burgos J, de Miguel M, Moreno S.   +21 more
europepmc   +1 more source